Holen Sie sich die Stockscreener-App
9.31
6.43%
-0.64
Handel nachbörslich:
9.31
Schlusskurs vom Vortag:
$9.95
Offen:
$9.97
24-Stunden-Volumen:
2.22M
Relative Volume:
0.79
Marktkapitalisierung:
$1.06B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-294.51M
KGV:
-2.6152
EPS:
-3.56
Netto-Cashflow:
$-244.42M
1W Leistung:
+1.53%
1M Leistung:
-2.72%
6M Leistung:
-30.83%
1J Leistung:
-79.09%
1-Tages-Spanne:
$9.25
$9.97
1-Wochen-Bereich:
$9.00
$10.23
52-Wochen-Spanne:
$6.36
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Vergleichen Sie DYN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
9.31 | 1.41B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics Narrowed Its Loss And Won Analyst Support - Finimize
Dyne Therapeutics extends cash runway as it advances key drug programs - Investing.com Australia
Dyne Therapeutics, Inc. Q2 Loss Increases, Misses Estimates - Nasdaq
Dyne (DYN) Expects Funding to Sustain Operations Through 2027 - GuruFocus
Dyne (DYN) Advances Clinical Programs and Strengthens Financial Position - GuruFocus
Dyne Therapeutics Extends Cash Runway to Q3 2027, Advances Clinical Trials for DM1 and DMD - Quiver Quantitative
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | DYN Stock News - GuruFocus
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
What is the dividend policy of Dyne Therapeutics Inc. stockOutstanding capital appreciation - jammulinksnews.com
What is the risk reward ratio of investing in Dyne Therapeutics Inc. stockDiscover breakthrough investment opportunities - jammulinksnews.com
Why is Dyne Therapeutics Inc. stock attracting strong analyst attentionUnlock exclusive trading strategies for gains - jammulinksnews.com
How many analysts rate Dyne Therapeutics Inc. as a “Buy”Exceptional market positioning - jammulinksnews.com
What is Dyne Therapeutics Inc. company’s growth strategyDiscover market opportunities with expert help - jammulinksnews.com
Should I hold or sell Dyne Therapeutics Inc. stock in 2025Breakthrough investment results - jammulinksnews.com
What makes Dyne Therapeutics Inc. stock price move sharplyRecord-setting profit potential - jammulinksnews.com
What are analysts’ price targets for Dyne Therapeutics Inc. in the next 12 monthsGet insider insights into market trends - jammulinksnews.com
What are the technical indicators suggesting about Dyne Therapeutics Inc.Track emerging stocks with high growth potential - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - ETX View
Dyne Therapeutics Inc. Stock Analysis and ForecastBreakout profit opportunities - Autocar Professional
What analysts say about Dyne Therapeutics Inc. stockFree Stock Market Return Analysis - Autocar Professional
What drives Dyne Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Is Dyne Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
Dyne Therapeutics (NASDAQ:DYN) Price Target Lowered to $9.00 at JPMorgan Chase & Co. - MarketBeat
Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Scott Bessent, Elliott Management, Citadel Investment Group, Balyasny Asset Management, Qualys Inc (QLYS), Dyne Therapeutics Inc (DYN), and More - Insider Monkey
Dyne Therapeutics (DYN) Stock Rises as CEO Increases Stake - GuruFocus
Dyne shares up after CEO buys stock (DYN:NASDAQ) - Seeking Alpha
Former Biogen VP Who Led SPINRAZA Success Joins Satellos to Advance DMD Treatment - Stock Titan
Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI - MSN
Strategic Confidence in Dyne Therapeutics: Insider Backing and Breakthroughs in Rare Disease Therapies - AInvest
DYN CEO Makes Significant Stock Purchase, Shares Rise | DYN Stoc - GuruFocus
How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.32%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):